Our research in Immunology
Intended for healthcare professionals, scientific audiences and media.
Pursuing pathbreaking science in Immunology
Hear from our Board Chair and CEO, Giovanni Caforio, M.D., about our commitment to elevating patient care to new standards to deliver what matters most – the promise of living a better life.
At Bristol Myers Squibb, we are working to deliver meaningful solutions that address unmet needs in rheumatology, gastroenterology, dermatology, pulmonology and neurology. While there has been progress with medicines for immune-mediated diseases, people living with these conditions may not respond to available treatments. Many continue to endure chronic symptoms and disease progression that can take a toll on their daily life.
Our goal is to restore some of what immune-mediated diseases have taken away — empowering patients and their loved ones to take back their lives.
Immunology focus areas
Our scientific innovation
Bristol Myers Squibb is focused on delivering scientific innovation with the empathy and urgency needed to advance care for people living with immune-mediated diseases.
As we continuously build and expand our portfolio, our teams work to identify mechanisms that may reset and promote balance in the immune system, with the goal of achieving long-term remission and, ultimately, curative therapies.
Discover how Bristol Myers Squibb’s pioneering research with tyrosine kinase 2 (TYK2) is changing how scientists tackle the challenge of immune-mediated diseases.
Hear from Jonathan Sadeh, MD, MSc, senior vice president of Immunology and Fibrosis Development at Bristol Myers Squibb, about how the company aims to build a robust immunology portfolio with pathbreaking science that addresses the unmet needs of people living with immune-mediated diseases.
Alyssa Johnsen, MD, PhD, vice president & head of clinical development, Immunology & Fibrosis at Bristol Myers Squibb, shares her perspective on the great strides that have been made in the science of modulating the body's immune response to treat disease.
Meet our Immunology researchers
Our presence at upcoming conferences
American Society of Nephrology (ASN) Kidney Week
Congress of Clinical Rheumatology (CCR) East
European Alliance of Associations for Rheumatology (EULAR) Congress
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Annual Meeting
International Congress on Systemic Lupus Erythematosus and the Korean College of Rheumatology Annual Scientific Meeting & International Symposium (LUPUS & KCR)
Lupus Academy Annual Meeting
Rheumatology Dermatology Society (RDS) Annual Meeting
American College of Rheumatology (ACR) Convergence
Congress of Clinical Rheumatology (CCR) West
European Lupus Meeting
Immunology Annual Meeting
International Society of Nephrology (ISN) World Congress of Nephrology (WCN)
Lupus 21st Century Conference
Rheumatology Winter Clinical Symposium (RWCS)
Advances in Inflammatory Bowel Diseases (AIBD) Conference
Crohn's & Colitis Congress
European Crohn's and Colitis Organization (ECCO) Congress
Gastroenterology Updates IBD and Liver Disease (GUILD) Conference
North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting
World Congress of Gastroenterology (WCOG)
American College of Gastroenterology (ACG) Annual Scientific Meeting
Digestive Disease Week (DDW)
Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) Annual Conference
United European Gastroenterology (UEG) Week
American Academy of Dermatology (AAD) Annual Meeting
Congress of the Skin Inflammation & Psoriasis International
Dermatology Education Foundation (DEF) Essential Resource Meeting (DERM) NP+PA Conference
Europe Dermatology Forum (EDF) Annual Meeting
European Society for Pediatric Dermatology (ESPD) Congress
Fall Clinical Dermatology Conference
Fall Clinical Real World Dermatology (RWD)
Inflammatory Skin Disease Summit (ISDS)
International Societies for Investigative Dermatology (ISID)
Maui Derm NP+PA Summer Live
Revolutionizing Atopic Dermatitis (RAD) Conference
Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference
Winter Clinical Dermatology Conference - Hawaii
American Academy of Dermatology (AAD) Innovation Academy
Cytokines Annual Meeting
European Academy of Dermatology and Venereology (EADV) Symposium
European Society for Dermatological Research (ESDR) Annual Meeting
Fall Clinical Board Immersion
Fall Clinical Dermatology Conference for Physician Assistants (PAs) and Nurse Practitioners (NPs)
Group For Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
International Dermatology Outcome Measures (IDEOM) Annual Meeting
International Society on Atopic Dermatitis (ISAD) Symposium
Maui Derm NP+PA Fall Live
Reunión Anual de Dermatólogos Latinoamericanos (RADLA)
Society of Dermatology Physician Assistants (SDPA) Annual Fall Conference
European Academy of Dermatology and Venereology (EADV) Congress
World Congress of Dermatology
American Academy of Neurology (AAN) Annual Meeting
Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting
European Charcot Foundation Annual Meeting
International Multiple Sclerosis Cognition Society (IMSCOGS) Annual Meeting
World Congress of Neurology (WCN)
Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
European Academy of Neurology (EAN) Congress
European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress
Treatment and Research in Multiple Sclerosis (triMS) Online Conference
Every day, each of us works to improve outcomes for patients fighting serious immune-mediated diseases. We're creative thinkers motivated by the practical application of our work, and innovators unafraid to step into uncharted territory. Together, we're building a better future for each other and the patients who need us most.
Over 20 years ago, Bristol Myers Squibb pioneered the science of modulating the body’s immune response to treat disease, beginning with the company’s research in rheumatoid arthritis (RA). Building on that foundation, we continue to pursue pathbreaking science across rheumatic diseases including RA, psoriatic arthritis, lupus and ankylosing spondylitis. Fueled by the possibility to help more patients, we are following the science to tailor therapies to individual needs, improve outcomes and expand treatment options.
Subhashish Banerjee, MD, vice president & disease area head, Rheumatology and Dermatology at Bristol Myers Squibb, shares how the company is leveraging a pathways-based approach to advance research and ultimately elevate care for patients in need of new treatment options in systemic lupus erythematosus (SLE), also known as lupus.
Bristol Myers Squibb is pursuing innovative research to potentially change the course of gastrointestinal immune-mediated diseases, including inflammatory bowel disease (IBD) (which includes ulcerative colitis and Crohn's disease) and eosinophilic esophagitis (EoE). Our scientific innovations have the potential to provide relief and remission to people living with these conditions.
Through Bristol Myers Squibb’s pioneering exploration of immune pathways implicated in dermatologic conditions, our discovery team’s research is leading to the potential for safe, effective, category-defining new therapies that may address the pressing treatment gaps that continue to exist for people living with these conditions. With a highly focused pipeline, we are pursuing novel treatments for psoriasis and atopic dermatitis and exploring a broad range of serious dermatologic conditions in our early research.
At Bristol Myers Squibb, we are focused on delivering solutions that may help preserve physical and cognitive function in people living with neurological conditions like multiple sclerosis (MS). Building on our experience, we are pursuing pathbreaking science to improve care for those impacted by the disease. By helping restore some of what MS has taken away, we aim to empower people living with MS and their loved ones to take back control of their lives.
Bristol Myers Squibb is committed to applying expertise regarding the role of fibrosis in the development of several immune-mediated diseases to advance new treatments that go beyond symptom relief and address the underlying causes of disease.
Hear Bruce Ellsworth, PhD, scientific executive director, Medicinal Chemistry, and Aryeh Fischer, MD, Lung Fibrosis clinical development lead, discuss how Bristol Myers Squibb is leveraging its deep expertise in medicinal chemistry and disease biology to research potential treatments for pulmonary fibrosis.